Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2019-03-18 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
2019年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2019 third extraordinary shareholders' meeting of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal witness statements. The content focuses on the announcement of voting results from a shareholders' meeting rather than the meeting materials or the full report. The document length is short (1587 characters), and it provides detailed voting outcomes and legal opinions, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). It is not an AGM Information presentation, nor a full Annual or Interim Report, nor a Proxy Solicitation. Therefore, the best classification is DVA with high confidence.
2019-03-18 Chinese
关于召开2019年第三次临时股东大会的提示性公告
Regulatory Filings Classification · 90% confidence The document is a notice about the convening of the 2019 third extraordinary general meeting of shareholders for the company 中源协和细胞基因工程股份有限公司. It includes details about the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is about 3100 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation of proxies or detailed information statements, it is best classified as a Regulatory Filing (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories exactly. The document is not a report publication announcement because it does not mention any report being published or attached, nor is it a certification or legal proceeding. Hence, the best classification is Regulatory Filings (RNS).
2019-03-12 Chinese
2019年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2019 Third Extraordinary General Meeting of Shareholders" of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes the meeting agenda, voting procedures, and two main proposals: adjustment of 2018 audit fees and amendments to the company's articles of association. The content is focused on the meeting logistics, shareholder voting, and legal compliance related to the meeting. There is no detailed financial data or comprehensive financial statements, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a voting results declaration (DVA) because it does not provide final voting outcomes, only the agenda and procedures. The document is clearly meeting materials provided to shareholders for the Extraordinary General Meeting, which fits the definition of AGM Information (AGM-R). The document length is under 5,000 characters, but it contains substantive meeting materials, not just an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is AGM Information (AGM-R).
2019-03-08 Chinese
章程（修订稿）
Governance Information Classification · 100% confidence The document is a detailed company charter (章程) for 中源协和细胞基因工程股份有限公司, outlining the company's organizational structure, shareholder rights, board responsibilities, and governance rules. It references Chinese company law and securities law, and extensively covers shareholder meetings, voting rights, board composition, and other governance matters. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a brief announcement or a transcript. The content aligns with a Governance Information report detailing internal rules, board structure, and governance practices. The document length (15,000 characters) and detailed content confirm it is the actual governance document, not just an announcement. Therefore, the appropriate classification is Governance Information (CGR).
2019-03-01 Chinese
关于召开2019年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about the convening of the 2019 third extraordinary general meeting of shareholders, including details about the meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain financial statements or results but rather logistical and procedural information about the shareholder meeting. The document length is under 5,000 characters and it is an announcement of a meeting rather than a report or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2019-03-01 Chinese
九届二十八次临时董事会会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 中源协和细胞基因工程股份有限公司 dated March 2019. It details decisions made by the board regarding audit fee adjustments, amendments to the company bylaws, and the scheduling of a shareholders meeting. The document is short (840 characters) and primarily announces board decisions rather than providing detailed financial data or full reports. It does not contain full audit reports, financial statements, or detailed management analysis. It also references other announcements for the bylaws amendment and shareholders meeting notice. Therefore, this document fits best under Board/Management Information (MANG) as it announces board resolutions and management decisions.
2019-03-01 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.